Please ensure Javascript is enabled for purposes of website accessibility

Why Patheon N.V. Is Soaring Today

By Brian Feroldi - May 15, 2017 at 11:05AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares skyrocketed after the company accepted a takeover bid from Thermo Fisher Scientific.

What happened

In response to the company accepting a buyout offer, shares of Patheon N.V. (NYSE: PTHN), a provider of development and manufacturing services for the pharmaceutical industry, jumped 33% as of 10:45 a.m. EDT on Monday.

So what

Thermo Fisher Scientific (TMO -0.79%) has agreed to acquire Patheon for $35 a share. That represents a 35% premium over the stock's closing price on Friday. The deal values Patheon at $7.2 billion when including the $2 billion of net debt on the company's balance sheet.

businessmen shaking hands and exchanging money

Image source: Getty Images.

Thermo Fisher's management team said that this deal will give the company an immediate foothold in the $40 billion contract development and manufacturing organization (CDMO) market. In addition, the acquisition is expected to be "immediately and significantly" accretive to its adjusted earnings per share. Current estimates call for the transaction to add $0.30 in adjusted EPS in the first full year after closing.

Thermo Fisher said that it will be funding the deal with $5.2 billion in debt and $2 billion in equity. If the deal wins regulatory approval, it is expected to close before the end of the year.

Now what

This looks to be a done deal since two of Patheon's largest shareholders -- JLL Partners and Royal DSM -- have already agreed to tender their shares as part of this transaction. These two owners hold roughly 73% of Patheon shares so they have enough voting power to force the deal to go through.

With Patheon's shares trading within $0.50 of the buyout price, it probably makes sense for shareholders to take a victory lap and hit the sell button. They should then think about reinvesting their proceeds into a few promising stock ideas.

Brian Feroldi has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Thermo Fisher Scientific Inc. Stock Quote
Thermo Fisher Scientific Inc.
TMO
$597.36 (-0.79%) $-4.75

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
402%
 
S&P 500 Returns
129%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.